These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 10679070)

  • 41. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
    Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
    Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes.
    Dadaglio G; Morel S; Bauche C; Moukrim Z; Lemonnier FA; Van Den Eynde BJ; Ladant D; Leclerc C
    Int Immunol; 2003 Dec; 15(12):1423-30. PubMed ID: 14645151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope.
    Bakker AB; van der Burg SH; Huijbens RJ; Drijfhout JW; Melief CJ; Adema GJ; Figdor CG
    Int J Cancer; 1997 Jan; 70(3):302-9. PubMed ID: 9033632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay.
    Griffioen M; Borghi M; Schrier PI; Osanto S
    Int J Cancer; 2001 Aug; 93(4):549-55. PubMed ID: 11477559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
    Prins RM; Odesa SK; Liau LM
    Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
    Snyder JT; Belyakov IM; Dzutsev A; Lemonnier F; Berzofsky JA
    J Virol; 2004 Jul; 78(13):7052-60. PubMed ID: 15194781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
    Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Teates D; Neese P; Grosh WW; Petroni G; Engelhard VH; Slingluff CL
    Int J Cancer; 2001 Jun; 92(5):703-11. PubMed ID: 11340576
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
    Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
    Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
    Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
    J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice.
    Firat H; Cochet M; Rohrlich PS; Garcia-Pons F; Darche S; Danos O; Lemonnier FA; Langlade-Demoyen P
    Int Immunol; 2002 Aug; 14(8):925-34. PubMed ID: 12147629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
    Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
    J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.
    Kim S; Li L; McMurtrey CP; Hildebrand WH; Weidanz JA; Gillanders WE; Diamond MS; Hansen TH
    J Immunol; 2010 Apr; 184(8):4423-30. PubMed ID: 20212098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.
    Lacey SF; La Rosa C; Kaltcheva T; Srivastava T; Seidel A; Zhou W; Rawal R; Hagen K; Krishnan A; Longmate J; Andersson HA; St John L; Bhatia R; Pullarkat V; Forman SJ; Cooper LJ; Molldrem J; Diamond DJ
    Blood; 2011 Aug; 118(8):2159-69. PubMed ID: 21719601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.